Jehan De Soyza , Josephine Richards , Philip House
Purpose : To evaluate the presence of glistenings in intra-ocular lenses used in Australia and New Zealand. Method: An online collaborative surgical quality audit by 29 fellows of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) was conducted from January 2015 to February 2017. Participants graded severity of glistenings from 0-4 according to a published photographic scale. Informa- tion gathered included the type of lens, ocular comor- bidities, date implanted and symptoms.
Results: Of 196 IOLs with glistenings, implanted between 1995 and 2016, 184 were from the Alcon Acrysof range. The remaining 12 IOLs were from
6 different ranges from 5 other manufacturers. Of the Acrysof IOLs, 40% (78) were implanted after 2012. Grade 3 glistenings comprised 22% (44) of the cases reported and were similarly present across the entire time range of implantation. Symptoms potentially attributable to the presence of glistenings were reported in 39% (76) of eyes. These included decreased contrast sensitivity (3); decreased vision (28); glare (21); trouble with vision when driving during the day, night or in wet conditions (12); trouble with reading (12). In 70% (137) of eyes, no complaints were reported. Eyes with risk factors for disrupted blood aqueous barrier comprised 53%
(104) of cases.
Conclusion: Glistenings were most commonly reported in Acrysof IOLs, including those implanted subsequent to 2012. Grade 3 glistenings were reported with similar frequency, before and after 2013. Clinicians attributed symptoms to glistenings in 39% of cases. Risk factors for disrupted blood aqueous barrier were notably common in this series. Jehan
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY